Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia

Research output: Contribution to journalLetter


  • Christian M Zwaan
  • Dirk Reinhardt
  • Brenda Gibson
  • Lucas Moreno
  • Karsten Nysom
  • Susumu Nakahara
  • Fei Huang
  • Wangda Zhou
  • Dolly A Parasrampuria
  • Sepideh Nemat

Colleges, School and Institutes

External organisations

  • NIHR Birmingham Biomedical Research Centre, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust
  • Department of Neurology, University Hospital Essen, Essen, Germany.
  • Royal Hospital for Sick Children Glasgow
  • Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Janssen R&D, Tokyo, Japan.
  • Janssen Research and Development, LLC, Spring House, PA, USA.
  • Janssen Pharmaceutical Companies of Johnson & Johnson, High Wycombe, UK.
  • Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands
  • Hospital Niño Jesús, Madrid, Spain


Original languageEnglish
Pages (from-to)e7-e11
Number of pages4
JournalBritish Journal of Haematology
Issue number3
Early online date7 Mar 2019
Publication statusPublished - 1 Aug 2019


  • CDKN2B, DNA methylation, ESR1, acute myeloid leukaemia, cytarabine, decitabine

ASJC Scopus subject areas